India tightens regulation on generics manufacturers

Home/Policies & Legislation | Posted 08/02/2019 post-comment0 Post your comment

The pharmaceutical industry in India ranks third in the world in terms of volume and is the largest provider of generic medicines globally. However, concerns over the quality of generics manufacturing have affected utilization in India. This is demonstrated by poor sales in Jan Aushadhi outlets, which are government-run retail outlets providing generic medicines at an affordable price.

143 AA010952

‘The confidence in generic medicines isn’t up to the mark among people, which reflects in the sales at the Jan Aushadhi stores. Of the 3,000 plus stores that we have, barely 10 to 15 have a turnover of more than Rs 50,000,” said Dr S Eswara Reddy, Drug Controller General of India.

To address these concerns and boost public confidence in generic medicines, stringent quality control measures will be put in place. These will oblige manufacturers of generic medicines seeking licences to demonstrate quality and safety equivalence to an approved reference product.

Dr R Chandrashekhar, Deputy Drug Controller, Central Drugs Standard Control Organization states: ‘It is part of the data collected under the BA/BE (bioavailability and bioequivalence) study, wherein the reference product or the first brand will be given by the drug controller that is duly tested’.

‘The onus will lie on the generics manufacturer to prove that the quality of their drug is similar to the branded one’, he said during the 70th Indian Pharmaceutical Congress.

At the moment, many states do not have their own drug testing laboratories, and only a small number are accredited by the National Accreditation Board for Testing and Calibration Laboratories. Dr Reddy’s reports that resources have been allocated, the workforce has been trained and regulatory standards are in the process of being upgraded up to an international standard, so that the Drugs and Cosmetics Act can be uniformly implemented across the country. He estimates that nearly 70% of generic manufacturers in India are reasonably compliant, and states that the focus will be on manufacturers who are not compliant.

Related article
Jan Aushadhi and affordability and accessibility of medicines in India

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010